Placebo News and Research

RSS

Study initiates hydroxychloroquine clinical trial to prevent COVID-19 in healthy people

Rush University Medical Center has opened enrollment for a new clinical trial investigating whether the drug hydroxychloroquine is better than a placebo in preventing COVID-19 infection in healthy people working in health care settings.

12 Jun 2020

Aspirin reduces hereditary colorectal cancer risk

Aspirin reduces colorectal cancer risk by half in individuals at high genetic risk. Preventive efficacy is prolonged for 10-20 years after treatment with aspirin.

11 Jun 2020

Antihypotensive agent for sepsis disrupts the immune system, increases susceptibility to infections

Patients who go into shock caused by sepsis (septic shock) are treated with the antihypotensive agent norepinephrine.

11 Jun 2020

Age-related structural brain changes are linked to hormone-level changes

Sex hormones influence the structure and function of the brain, but little is known about the effect of hormone therapies (HT) on changes in the brain during menopause.

10 Jun 2020

GlobalData: Use of hydroxychloroquine as COVID19 treatment continues to be debated

There is no clinical evidence that hydroxychloroquine is effective against COVID19. Some studies using hydroxychloroquine have shown no benefits or even an increase in risk of death, but the number of clinical trials investigating hydroxychloroquine as a primary or secondary intervention continues to expand to determine whether the drug candidate is a key contender as a therapeutic or not, says GlobalData, a leading data and analytics company.

10 Jun 2020

Registered COVID-19 clinical trials lack key features to optimize their scientific value

Most of the registered clinical trials of potential treatments for COVID-19 underway as of late March were designed in ways that will greatly limit their value in understanding potential treatments, according to a study from researchers at Johns Hopkins Bloomberg School of Public Health.

10 Jun 2020

Fecal transplants could be used as treatment for non-alcoholic fatty liver disease

A new study from Lawson Health Research Institute and Western University suggests that fecal transplants could be used as a treatment for non-alcoholic fatty liver disease.

9 Jun 2020

Cannabis temporarily reduces severity of PTSD symptoms

People suffering from post-traumatic distress disorder report that cannabis reduces the severity of their symptoms by more than half, at least in the short term, according to a recent study led by Carrie Cuttler, a Washington State University assistant professor of psychology.

9 Jun 2020

High-salt diet may modulate the gut microbiome

Particularly in females with untreated hypertension, reducing salt intake to what's considered a healthier level appears to be good for both their gut microbiome and their blood pressure, scientists report.

9 Jun 2020

Empagliflozin reduces CKD progression in type 2 diabetics with cardiovascular disease

Empagliflozin (EMPA), a selective inhibitor of sodium/glucose cotransporter 2 (SGLT2 inhibitors, "gliflozines"), reduces CKD progression in type 2 diabetics (T2D) with cardiovascular disease, presumably by lowering intraglomerular pressure.

9 Jun 2020

Drug offers hope for patients with primary hyperoxaluria type 1

Primary hyperoxaluria type 1 (PH1) is an autosomal recessive inherited disorder that begins in childhood and adolescence.

8 Jun 2020

Using antibodies to detect Alzheimer’s disease

News-Medical speaks to Professor Vendruscolo about his research that uses antibodies to detect Alzheimer's disease, which could help to improve drug discovery.

8 Jun 2020

Newer data confirms survival advantages, but also side effects for ribociclib in breast cancer

In 2017 and 2019, the German Institute for Quality and Efficiency in Health Care had already examined the advantages and disadvantages of ribociclib in combination with an aromatase inhibitor or fulvestrant in comparison with the appropriate comparator therapy in patients after menopause, with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.

5 Jun 2020

Study shows how psychedelic drug psilocybin works in the brain

Perhaps no region of the brain is more fittingly named than the claustrum, taken from the Latin word for "hidden or shut away."

5 Jun 2020

WHO resumes hydroxychloroquine drug trial in COVID-19

The coronavirus disease (COVID-19) has rippled across the world with a devastating effect. As scientists raced to find an effective treatment for patients, existing malaria and rheumatoid arthritis drug hydroxychloroquine became one of the most popular candidates.

5 Jun 2020

Trial results show efficacy of netakimab for treating moderate-to-severe plaque psoriasis

Netakimab is a humanized anti-interleukin 17A antibody approved for the treatment of moderate-to-severe plaque psoriasis.

5 Jun 2020

Assessing the integrity of remdesivir clinical trial during COVID-19 pandemic

As acknowledged in the first remdesivir double-blind placebo-controlled clinical trial addressing treatment for COVID-19 recently published in Lancet (Wang, et al., April 29, 2020), a statistician at Rutgers Cancer Institute of New Jersey was called on to guard the integrity of that trial.

4 Jun 2020

Placebo News and Research

Study initiates hydroxychloroquine clinical trial to prevent COVID-19 in healthy people

Aspirin reduces hereditary colorectal cancer risk

Antihypotensive agent for sepsis disrupts the immune system, increases susceptibility to infections

Age-related structural brain changes are linked to hormone-level changes

GlobalData: Use of hydroxychloroquine as COVID19 treatment continues to be debated

Registered COVID-19 clinical trials lack key features to optimize their scientific value

Fecal transplants could be used as treatment for non-alcoholic fatty liver disease

Cannabis temporarily reduces severity of PTSD symptoms

High-salt diet may modulate the gut microbiome

Empagliflozin reduces CKD progression in type 2 diabetics with cardiovascular disease

Drug offers hope for patients with primary hyperoxaluria type 1

Using antibodies to detect Alzheimer’s disease

Newer data confirms survival advantages, but also side effects for ribociclib in breast cancer

Study shows how psychedelic drug psilocybin works in the brain

WHO resumes hydroxychloroquine drug trial in COVID-19

Trial results show efficacy of netakimab for treating moderate-to-severe plaque psoriasis

Assessing the integrity of remdesivir clinical trial during COVID-19 pandemic

DFG to establish ten new Collaborative Research Centers

Hydroxychloroquine not able to prevent development of COVID-19, UMN trial shows

Original Hamilton Rating Scale for Depression was unstructured, indicates study

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News